Literature DB >> 3140121

Haemolytic-uraemic syndrome: a 10-year follow-up study of 73 patients.

M de Jong1, L Monnens.   

Abstract

Long-term follow-up is presented of 73 patients suffering from the haemolytic-uraemic syndrome 10 years after the acute initial illness. The patients were subdivided into three groups, according to the criteria proposed by Gianantonio and based on the duration of oliguria and/or anuria. Four out of 38 patients belonging to the first group (oliguria for less than 7 days) had a slightly increased blood pressure as the only sequela. Two patients out of group two (n = 29, oliguria for 7-14 days or anuria for less than 7 days) had a diminished GFR and a reduced concentrating capacity, some proteinuria, and mild hypertension. Five other patients had slight proteinuria (less than 500 mg/24 h) and one of them a mild hypertension. All six patients belonging to the third group (oliguria for more than 14 days or anuria for more than 7 days) had late sequelae: two started haemodialysis more than 10 years after the initial phase; three have a decreased GFR and concentrating capacity. The unique remaining patient with a normal GFR without hypertension has a decreased concentrating capacity. The importance of careful treatment in children with a decreased GFR 2 years after the initial phase is stressed.

Entities:  

Mesh:

Year:  1988        PMID: 3140121     DOI: 10.1093/oxfordjournals.ndt.a091684

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  3 in total

Review 1.  Haemolytic uraemic syndrome.

Authors:  W L Robson
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.022

2.  Childhood haemolytic uraemic syndrome: long-term outcome and prognostic features.

Authors:  A Kelles; M Van Dyck; W Proesmans
Journal:  Eur J Pediatr       Date:  1994-01       Impact factor: 3.183

3.  Haemolytic uraemic syndrome: prognostic factors in children over 3 years of age.

Authors:  C Renaud; P Niaudet; M F Gagnadoux; M Broyer; R Habib
Journal:  Pediatr Nephrol       Date:  1995-02       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.